Pre-illness data reveals differences in multiple metabolites and metabolic pathways in those who do and do not recover from infectious mononucleosis. — CFSMEATLAS
Pre-illness data reveals differences in multiple metabolites and metabolic pathways in those who do and do not recover from infectious mononucleosis.
Jason, Leonard A, Conroy, Karl E, Furst, Jacob et al. · Molecular omics · 2022 · DOI
Quick Summary
This study looked at blood samples taken from college students before they got sick to see if certain chemical markers could predict who would recover from mononucleosis and who would develop ME/CFS instead. Researchers found that people who later developed ME/CFS had different levels of certain chemicals in their blood before they even got sick, particularly those involved in energy production and immune function. Using a computer model based on these chemical differences, they could correctly predict with 97% accuracy which people would recover and which would develop ME/CFS.
Why It Matters
This study provides evidence that ME/CFS susceptibility may have detectable metabolic signatures present before illness onset, suggesting biological predisposition rather than purely infectious trigger. Identifying pre-illness metabolic markers could enable risk stratification and early intervention strategies for vulnerable individuals exposed to triggering infections. These findings support the biological basis of ME/CFS and highlight specific metabolic pathways as potential therapeutic targets.
Observed Findings
Pre-illness blood samples from those who later developed ME/CFS showed significantly different metabolite levels compared to those who recovered from infectious mononucleosis.
Glutathione metabolism, nucleotide metabolism, and the TCA cycle were identified as dysregulated pathways in the ME/CFS group before illness onset.
A predictive model based on metabolite differences correctly classified 97.2% of study participants (94.4% sensitivity, 100% specificity).
These pre-illness metabolic differences are consistent with the elevated pro-inflammatory cytokine profiles previously observed in the same cohort.
Inferred Conclusions
Metabolic dysregulation present before infectious mononucleosis may predispose individuals to develop severe ME/CFS rather than recover.
Multiple metabolic pathways critical for immune response proliferation appear dysregulated in those who develop ME/CFS, suggesting fundamental differences in cellular energy and immune metabolism.
Measurable pre-illness biomarkers could potentially identify high-risk individuals before infection exposure.
Remaining Questions
Do these pre-illness metabolic differences exist in ME/CFS cases triggered by other infections or other onset mechanisms?
What causes the initial metabolic dysregulation, and is it genetic, environmental, or related to prior infections or immune priming?
What This Study Does Not Prove
This study does not prove that these metabolic differences cause ME/CFS—they may be correlates or markers of underlying vulnerability. The findings cannot explain the mechanism by which these metabolic differences lead to persistent illness after infection. Results require validation in independent cohorts and different populations before clinical application; the high accuracy may not generalize beyond this specific college-age population.